Anti-Human CD27 Recombinant Antibody (Varlilumab) (CAT#: TAB-H74)

Recombinant human antibody to Human CD27. Varlilumab is an immunotherapy designed to enhance the body's natural immune response by directly activating T cells that can specifically recognize and kill cancer cells.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Varlilumab pharmacokinetics and receptor occupancy.

Figure 1 Varlilumab pharmacokinetics and receptor occupancy.

Serum concentrations of varlilumab were determined by ELISA by using recombinant CD27-coated plates and anti-human IgG-horseradish peroxidase conjugate as a detection probe. Values represent the mean for patients in each cohort.

Burris, H. A., Infante, J. R., Ansell, S. M., Nemunaitis, J. J., Weiss, G. R., Villalobos, V. M., ... & Hawthorne, T. R. (2017). Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors. Journal of Clinical Oncology, 35(18), 2028-2036.

Figure 2 Varlilumab pharmacokinetics and receptor occupancy.

Figure 2 Varlilumab pharmacokinetics and receptor occupancy.

Percent receptor occupancy was determined by flow cytometry using anti-human IgG conjugate for detection of varlilumab and a noncompeting anti–CD27-labeled monoclonal antibody for identifying CD27 expression. Values respresent the percentage of CD8+/CD27+ T cells that stained positive with anti-human IgG treated at different dose levels.

Burris, H. A., Infante, J. R., Ansell, S. M., Nemunaitis, J. J., Weiss, G. R., Villalobos, V. M., ... & Hawthorne, T. R. (2017). Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors. Journal of Clinical Oncology, 35(18), 2028-2036.

Figure 3 Varlilumab pharmacokinetics and receptor occupancy.

Figure 3 Varlilumab pharmacokinetics and receptor occupancy.

Mean level of soluble CD27 as using a sandwich ELISA that is not obstructed by the presence of bound varlilumab. Black triangles (:) represent varlilumab dosing. ELISA, enzymelinked immunosorbent assay; Ig, immunoglobulin; PBMC, peripheral blood mononuclear cell; TIL, tumor-infiltrating lymphocytes.

Burris, H. A., Infante, J. R., Ansell, S. M., Nemunaitis, J. J., Weiss, G. R., Villalobos, V. M., ... & Hawthorne, T. R. (2017). Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors. Journal of Clinical Oncology, 35(18), 2028-2036.

Figure 4 Increase in responses to melanoma antigen in select patients who were treated with varlilumab.

Figure 4 Increase in responses to melanoma antigen in select patients who were treated with varlilumab.

Enumeration of CD8+ T-cell responses in HLA-A2– or HLAA3–positive patients with melanoma to the indicated melanoma-associated antigens. Peripheral blood mononuclear cells (PBMCs) from days 1, 29, and 85 were assayed for interferon-gamma production in response to antigen-presenting cells that were pulsed with selected melanoma antigen peptides after 2 weeks in vitro stimulation with a peptide cocktail. Values shown are the fold change on the basis of dividing the absolute counts for each peptide by the counts with control HIV gag–derived peptides. P values were calculated by using one-way analysis of variance for individual timepoints or unpaired Student t tests across timepoints. For patient 04-9002, PBMCs were directly stained for major histocompatibility complex multimer binding and representative dot plots are presented. ns, not significant.

Burris, H. A., Infante, J. R., Ansell, S. M., Nemunaitis, J. J., Weiss, G. R., Villalobos, V. M., ... & Hawthorne, T. R. (2017). Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors. Journal of Clinical Oncology, 35(18), 2028-2036.

Figure 5 Induced proliferations of T cell subsets and coexpression of costimulatory and coinhibitory receptors (immune checkpoint molecules).

Figure 5 Induced proliferations of T cell subsets and coexpression of costimulatory and coinhibitory receptors (immune checkpoint molecules).

Differences in short term (3 day) or long term (7 day) T cell cultures undergoing stimulations with varlilumab or control antibody (hIgG) show more CD8+ cells (a) entering the division cycle in the varlilumab-treated group. Numbers in the histograms refer to the percent of indicated cells (CD8+ or CD3+CD8-) that are dividing as reflected by CFSE staining (a bottom panel).

Ramakrishna, V., Sundarapandiyan, K., Zhao, B., Bylesjo, M., Marsh, H. C., & Keler, T. (2015). Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab. Journal for immunotherapy of cancer, 3(1), 37.

Figure 6 Induced proliferations of T cell subsets and coexpression of costimulatory and coinhibitory receptors (immune checkpoint molecules).

Figure 6 Induced proliferations of T cell subsets and coexpression of costimulatory and coinhibitory receptors (immune checkpoint molecules).

CD27+ proliferating CD4+ and CD8+ T cells were stained with antibodies to additional cell surface markers representing costimulatory (GITR, OX40, ICOS and 4-1BB) and coinhibitory (PD-1) molecules. Dividing CD8+ and CD4+ T cells show marked upregulation of costimulatory and coinhibitory molecules relative to non-dividing cells. Shaded histograms represent T cells stimulated with control antibody and anti-CD3 (OKT3). Numbers in the histograms refer to percent of T cells (dividing or non-dividing CD8 or CD4 cells) that are positive for the indicated costimulatory or coinhibitory marker.

Ramakrishna, V., Sundarapandiyan, K., Zhao, B., Bylesjo, M., Marsh, H. C., & Keler, T. (2015). Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab. Journal for immunotherapy of cancer, 3(1), 37.

Figure 7 Early detection of cytokines by varlilumab costimulated T cell subsets.

Figure 7 Early detection of cytokines by varlilumab costimulated T cell subsets.

T cells were preactivated with OKT3 for 46 h and post activated for 4 h with OKT3+ varlilumab or OKT3+ hIgG. Intracellular staining for IFNγ response in different T cell subpopulations (a) Naïve CD4+ (CD45RO ̶) and memory (CD45RO+) and (b) naïve CD8+ (CD45RO ̶) and memory (CD45RO+) T cells. Cells were co-stained for the activation marker CD69. Numbers in individual plots refer to percent IFNγ+ cells.

Ramakrishna, V., Sundarapandiyan, K., Zhao, B., Bylesjo, M., Marsh, H. C., & Keler, T. (2015). Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab. Journal for immunotherapy of cancer, 3(1), 37.


Specifications

  • Host Species
  • human
  • Derivation
  • human
  • Type
  • IgG1 - kappa
  • Specificity
  • CD27 (TNFRSF7, tumor necrosis factor receptor superfamily member 7) [Homo sapiens]
  • Species Reactivity
  • Human
  • Applications
  • ELISA, IP, FC, FuncS, Neut, IF, ICC
  • Generic Name
  • varlilumab
  • MW
  • 146.0 kDa
  • Related Disease
  • Solid tumors

Product Property

  • Purity
  • >95%, by SDS-PAGE with silver staining, under reducing conditions.

Applications

  • Application Notes
  • The CD27 antibody has been reported in applications of ELISA, FC, S-ELISA, Stim, CFSE, Inhib, Activ.
    ELISA: Purified T cells (1 × 105 T cells/well) were added to wells of a 96 well plate or 1.5 × 106 cells/well of a 24 well plate) and stimulated with Abs for different durations from 24 to 72 h at 37 °C in a humidified CO2 incubator. Cells were cultured in RPMI 1640 basal medium supplemented with 10 % heat-inactivated fetal bovine serum, L-Glutamine, and penicillin/streptomycin. Cell-free culture supernatants were obtained by centrifugation and frozen at −20 °C for cytokine and biomarker analysis.

Target

  • Alternative Names
  • varlilumab;CD27;CD27 molecule;TNFRSF7, tumor necrosis factor receptor superfamily, member 7;CD27 antigen;S152;Tp55;CD27L receptor;T cell activation antigen S152;T-cell activation antigen CD27;tumor necrosis factor receptor superfamily, member 7;T14;TNFRSF

Related Resources

  • Biosimilar Overview
Please refer to Varlilumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Varlilumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Varlilumab"

Afuco™ Anti-CD27 ADCC Recombinant Antibody (Varlilumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human antibody to Human CD27. Varlilumab is an immunotherapy designed to enhance the body's natural immune response by directly activating T cells that can specifically recognize and kill cancer cells.

See other products for "CD27"

Chimeric Antibody

CAT Product Name Application Type
TAB-018LC Human Anti-CD27 Recombinant Antibody (TAB-018LC) ELISA Chimeric antibody (rat/human)
TAB-019LC Human Anti-CD27 Recombinant Antibody (TAB-019LC) ELISA Chimeric antibody (rat/human)
TAB-020LC Human Anti-CD27 Recombinant Antibody (TAB-020LC) ELISA Chimeric antibody (rat/human)
TAB-021LC Human Anti-CD27 Recombinant Antibody (TAB-021LC) ELISA Chimeric antibody (rat/human)
TAB-040LC-F(E) Anti-Human CD27 Recombinant Antibody Fab Fragment (0155) SPR, FC Chimeric antibody (rabbit/human)

Humanized Antibody

Neutralizing Antibody

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-0547 Hi-Affi™ Rabbit Anti-CD27 Recombinant Antibody (clone DS547AB) WB, IHC, ICC, FC Rabbit IgG

Agonistic Antibody

CAT Product Name Application Type
MOB-096LC Human Anti-CD27 Recombinant Antibody (MOB-096LC) ELISA, FuncS, WB Human IgG1, κ

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-H74 Afuco™ Anti-CD27 ADCC Recombinant Antibody (Varlilumab), ADCC Enhanced ELISA, IP, FC, FuncS, Neut, IF ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-H74. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare